CJC-1295 (without DAC) and Tesamorelin Interaction

Monitor

Researched 90% confidence

CJC-1295 (without DAC) and Tesamorelin have an interaction requiring monitoring for interaction with 90% confidence. Both are GHRH analogs; combining offers no additional benefit. Both compounds affect the gi tract and pituitary, so monitoring these systems is recommended.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss

ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic

View full profile

Tesamorelin

GHRH Analog | Visceral Fat Reduction

Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..

Half-life: 26-38 minutes Typical dose: 1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) growth hormone, weight loss

ghrh receptor carcinogenic riskinsulin disruptingteratogenic

View full profile

Combined Organ Load

GI Tract

low

Pituitary

low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 (without DAC), Tesamorelin). Monitor accordingly.

2x 2 compounds affect insulin sensitivity (CJC-1295 (without DAC), Tesamorelin). Monitor fasting glucose and HbA1c.

2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), Tesamorelin). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with Tesamorelin?

Yes, but with caution. Both are GHRH analogs; combining offers no additional benefit. Regular monitoring is advised.

Is CJC-1295 (without DAC) and Tesamorelin safe together?

Based on documented research, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and Tesamorelin?

Both are GHRH analogs; combining offers no additional benefit. This assessment has 90% confidence and is based on documented research data.

How should I time CJC-1295 (without DAC) and Tesamorelin?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs Tesamorelin

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.